Human thyroxine binding globulin (TBG) promoter directs efficient and sustaining transgene expression in...

Area of Science:

• Hepatology
• Molecular Biology
• Gene Therapy

Background:

• The liver is a key metabolic organ and a primary target for gene therapy.
• Metabolic disorders often necessitate effective gene delivery to the liver.
• Evaluating promoter efficiency is crucial for successful hepatic gene therapy.

Purpose of the Study:

• To quantitatively assess the efficacy of six different promoters for liver gene therapy.
• To identify the optimal promoter for sustained and specific transgene expression in the liver.
• To optimize vector design for treating liver-associated metabolic disorders.

Main Methods:

• Lentivirus-mediated delivery of α1-antitrypsin transgene in the liver.
• Quantitative evaluation of six promoters: CMV, EF1α, PGK, apoE, TBG, and CYP2E1.
• Identification of the optimal TBG promoter fragment (-435bp to -26bp from TSS) for high-level expression.

Main Results:

• The TBG promoter demonstrated high activity, comparable to CMV and EF1α, and superior to PGK, apoE, and CYP2E1.
• A specific TBG promoter region (-435bp to -26bp) was identified for maximal transgene expression.
• TBG promoter conferred persistent and liver-specific transgene expression for several months.

Conclusions:

• The TBG promoter is a highly effective tool for hepatic gene therapy.
• Optimized TBG promoter sequences enhance transgene expression levels and specificity.
• This research facilitates the development of improved vectors for treating metabolic diseases via liver gene therapy.